2. Astellas Pharma and INC Research:
In April Astellas Pharma and INC Research announced they were expanding their relationship. The partners etched out a three-year FSP alliance that will provide the Japanese pharma giant with various services including clinical monitoring, trial master file management, site start-up, study-feasibility activities and clinical data management.
FSP work has whetted the appetites of Big Pharma players like Eli Lilly ($LLY), Merck ($MRK) and Sanofi ($SNY), all of which have expressed interest in further using the model, which delves more into data management, according to William Blair equity analyst John Kreger in an Outsourcing-Pharma article in March.
In addition to the those services, INC established a dedicated business unit that will focus on the delivery and implementation of the FSP services for Astellas. The two estimate the relationship will reduce costs up to 40%, while providing time savings in the range of 10% to 20% over its course.